世界最新医学信息文摘(连续型电子期刊)
世界最新醫學信息文摘(連續型電子期刊)
세계최신의학신식문적(련속형전자기간)
World Latest Medicine Information
2015年
62期
95-96
,共2页
胺碘酮%急性心肌梗死%室性心律失常
胺碘酮%急性心肌梗死%室性心律失常
알전동%급성심기경사%실성심률실상
Amiodarone%Acute myocardial infarction%Ventricular arrhythmia
目的:观察胺碘酮治疗高龄急性心肌梗死伴室性心律失常的近期疗效。方法研究对象源自于我院2013年12月至2014年12月收治的74例急性心肌梗死伴室性心律失常老年患者,按随机数字表法分为对照组(37例)与观察组(37例)。对照组患者接受常规治疗;观察组同时给予胺碘酮,观察两组治疗效果。结果观察组治疗总有效率89.2%显著高于对照组70.3%,两组比较差异有统计学意义(P<0.05)。结论胺碘酮治疗高龄急性心肌梗死伴室性心律失常能有效缓解患者临床症状,改善心功能,疗效确切,适合于临床推广。
目的:觀察胺碘酮治療高齡急性心肌梗死伴室性心律失常的近期療效。方法研究對象源自于我院2013年12月至2014年12月收治的74例急性心肌梗死伴室性心律失常老年患者,按隨機數字錶法分為對照組(37例)與觀察組(37例)。對照組患者接受常規治療;觀察組同時給予胺碘酮,觀察兩組治療效果。結果觀察組治療總有效率89.2%顯著高于對照組70.3%,兩組比較差異有統計學意義(P<0.05)。結論胺碘酮治療高齡急性心肌梗死伴室性心律失常能有效緩解患者臨床癥狀,改善心功能,療效確切,適閤于臨床推廣。
목적:관찰알전동치료고령급성심기경사반실성심률실상적근기료효。방법연구대상원자우아원2013년12월지2014년12월수치적74례급성심기경사반실성심률실상노년환자,안수궤수자표법분위대조조(37례)여관찰조(37례)。대조조환자접수상규치료;관찰조동시급여알전동,관찰량조치료효과。결과관찰조치료총유효솔89.2%현저고우대조조70.3%,량조비교차이유통계학의의(P<0.05)。결론알전동치료고령급성심기경사반실성심률실상능유효완해환자림상증상,개선심공능,료효학절,괄합우림상추엄。
ABSTRACT:Objective To observe the short-term curative effect of amiodarone in treating senile acute myocardial infarction complicated by ventricular arrhythmia. Methods 74 cases of elderly patients with acute myocardial infarction complicated by ventricular arrhythmia were taken as the research objects. According to the random number table method, the patients were divided into the control group (37 cases) and the observation group (37 cases). The control group received conventional treatment while the observation group was given amiodarone at the same time. The therapeutic effect of the two groups was observed. Results The total effective rate of the observation group was 89.2%which was significantly higher than 70.3%of the control group and the difference between the two groups was statistically significant (P<0.05). Conclusion Amiodarone in the treatment of elderly patients with acute myocardial infarction complicated by ventricular arrhythmia can effectively relieve the clinical symptoms and improve cardiac function. The curative effect is exact. It is suitable for clinical promotion.